Αρχική World News Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up... World News Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC Από Ogkologos - 2 Απριλίου, 2025 816 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer 24 Μαΐου, 2023 Research with integrity – referencing work is way more than just... 3 Μαΐου, 2023 Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors? 27 Ιουλίου, 2021 2022 ASCO Annual Meeting Research Round Up: New Research in Head... 25 Αυγούστου, 2022 Φόρτωση περισσοτέρων HOT NEWS Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... How does processed and red meat cause cancer and how much... Kelly Preston, Actress And Wife Of John Travolta, Dies From Breast...